16 September 2026 editorial review · Trial
VX-880 / zimislecel: phase 3 in T1D with a kidney transplant: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT06832410; RECRUITING; updated 2026-03-23; enrollment 10 (ESTIMATED); results not posted.
Endpoint comparison: Proportion of Participants who are Insulin Independent (At 1 year After VX-880 infusion).
Sources for this record: A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant (registry); Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes (peer-reviewed).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.